ARVN

Company Overview — What Does ARVINAS, INC. Do?

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut. ARVINAS, INC. (ARVN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John G. Houston and employs approximately 420 people. With a market capitalization of $725M, ARVN is one of the notable companies in the Healthcare sector.

ARVINAS, INC. (ARVN) Stock Rating — Reduce (April 2026)

As of April 2026, ARVINAS, INC. receives a Reduce rating with a composite score of 40.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ARVN ranks #2,847 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ARVINAS, INC. ranks #397 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARVN Stock Price and 52-Week Range

ARVINAS, INC. (ARVN) currently trades at $10.82. The stock lost $0.35 (3.1%) in the most recent trading session. The 52-week high for ARVN is $14.51, which means the stock is currently trading -25.4% from its annual peak. The 52-week low is $5.90, putting the stock 83.4% above its annual trough. Recent trading volume was 490K shares, suggesting relatively thin trading activity.

Is ARVN Overvalued or Undervalued? — Valuation Analysis

ARVINAS, INC. (ARVN) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.29x, versus the sector average of 2.75x. The price-to-sales ratio is 2.05x, compared to 1.66x for the average Healthcare stock.

At current multiples, ARVINAS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ARVINAS, INC. Profitability — ROE, Margins, and Quality Score

ARVINAS, INC. (ARVN) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -11.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.4% versus the sector average of -33.1%.

On a margin basis, ARVINAS, INC. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -111.2% (sector: -66.1%). Net profit margin stands at -90.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -45.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARVN Debt, Balance Sheet, and Financial Health

ARVINAS, INC. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.70x, indicating strong short-term liquidity. Total debt on the balance sheet is $600,000. Cash and equivalents stand at $102M.

ARVN has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ARVINAS, INC. is 44/100, reflecting average volatility within the normal range for its sector.

ARVINAS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ARVINAS, INC. reported revenue of $356M and earnings per share (EPS) of $-0.48. Net income for the quarter was $-63M. Gross margin was 100.0%. Operating income came in at $-104M.

In Q3 2025, ARVINAS, INC. reported revenue of $42M and earnings per share (EPS) of $-0.48. Net income for the quarter was $-35M. Revenue grew -59.1% year-over-year compared to Q3 2024. Operating income came in at $-44M.

In Q2 2025, ARVINAS, INC. reported revenue of $22M and earnings per share (EPS) of $-0.84. Net income for the quarter was $-61M. Revenue grew -70.7% year-over-year compared to Q2 2024. Operating income came in at $-72M.

In Q1 2025, ARVINAS, INC. reported revenue of $189M and earnings per share (EPS) of $1.14. Net income for the quarter was $83M. Revenue grew 646.2% year-over-year compared to Q1 2024. Operating income came in at $71M.

Over the past 8 quarters, ARVINAS, INC. has demonstrated a growth trajectory, with revenue expanding from $25M to $356M. Investors analyzing ARVN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARVN Dividend Yield and Income Analysis

ARVINAS, INC. (ARVN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARVN Momentum and Technical Analysis Profile

ARVINAS, INC. (ARVN) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

ARVN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ARVINAS, INC. (ARVN) ranks #397 out of 838 stocks based on the Blank Capital composite score. This places ARVN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARVN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARVN vs S&P 500 (SPY) comparison to assess how ARVINAS, INC. stacks up against the broader market across all factor dimensions.

ARVN Next Earnings Date

No upcoming earnings date has been announced for ARVINAS, INC. (ARVN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARVN? — Investment Thesis Summary

The quantitative profile for ARVINAS, INC. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 27/100 indicates premium valuation.

In summary, ARVINAS, INC. (ARVN) earns a Reduce rating with a composite score of 40.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARVN stock.

Related Resources for ARVN Investors

Explore more research and tools: ARVN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARVN head-to-head with peers: ARVN vs AZN, ARVN vs SLGL, ARVN vs VMD.